MedTrace Logo

Incidence of Emergence Delirium in the PACU

NCT04531020 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1421

Last updated 2022-02-15

No results posted yet for this study

Summary

Emergence delirium (ED) is serious complication in the postoperative period in paediatric anaesthesia, reported incidence is 20-60%. It is characterized by psychomotor and perception disorder with excitation of paediatric patients. Emergence delirium has impact on morbidity and even on mortality of paediatric patients in the postoperative period.

The potential risk factors for ED development include sevoflurane, which is the dominant anaesthetic agent used in the paediatric patients, and which is actually the only inhalation agent used for inhalation anaesthesia induction. The incidence of ED is higher in postoperative period, for example in the Post-anaesthesia Care Unit - PACU. Patients with ED are at higher risk of psychomotor anxiety, agitation, unintentional extraction of intravenous cannula, and nausea and vomiting. For the therapy of ED propofol, midazolam and eventually ketamine in a reduced dosage are used.

Conditions

  • Emergence Delirium

Interventions

DIAGNOSTIC_TEST

PAED measurement

The incidence of emergence delirium, defined as PAED score above 10 points minimally in one of the PAED score measurements. PAED score will be measured in 0., 5., 10., 15., and 20. minute after PACU admission.

Sponsors & Collaborators

  • Brno University Hospital

    lead OTHER

Principal Investigators

  • Petr Štourač, prof. MD., Ph.D. · Faculty of medicince Masaryk University and University Hospital Brno

Eligibility

Min Age
1 Month
Max Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-06-30
Completion
2022-01-01

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04531020 on ClinicalTrials.gov